IPI was founded in 2017 by scientists Timothy Springer and Andrew Kruse of Harvard Medical School.
IPI is located on the Harvard Medical School campus in Boston’s Longwood Medical and Academic Area.
IPI operates on an annual budget of $13 million.
Since 2017, IPI has made 9,000 antibodies and 240 antigens, now being evaluated for quality and performance.
IPI is financially secured by substantial gifts from co-founder Timothy Springer and project-specific grant funding secured by IPI scientists.
IPI employs approximately 40 people, mostly scientists and research associates staffing its antibody platform.
IPI is a nonprofit 501(c)3 organization.
IPI’s mission is to accelerate research and improve human health by providing scientists with openly shared protein tools capable of illuminating fundamental biological processes.
At IPI’s core is a scientific platform matching rare, state-of-the-art technology with skilled scientists from top institutions around the world.
Our scientists apply their protein expertise to scalable, multidisciplinary projects that focus on the basic molecular processes that drive human biology, especially in neurobiology, immunology and cancer.